Diabetes Therapy

Development of CS-917 for the treatment of type 2 diabetes to resume

Published in Obesity and Diabetes Week, August 15th, 2005

Sankyo Co., Ltd., and Metabasis Therapeutics, Inc., (MBRX) jointly announced that Sankyo plans to resume full development of CS-917 including a phase IIb clinical trial expected to begin in the fourth quarter of 2005.

CS-917 is a first-in-class, orally active, gluconeogenesis inhibitor that has shown promise as a treatment for patients with type 2 diabetes.

A phase IIb study evaluating CS-917 was halted earlier this year after two serious adverse events occurred during a phase I study that combined CS-917 with the diabetes drug metformin. After a comprehensive review of the program and the events and data surrounding these two events, Sankyo has...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2005-08-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry